Acrannolife Genomics Profile
Key Indicators
- Authorised Capital ₹ 8.00 M
- Paid Up Capital ₹ 6.53 M
- Company Age 10 Year, 6 Months
- Last Filing with ROC 31 Mar 2023
- Open Charges ₹ 5.33 Cr
- Revenue Growth 52.78%
- Profit Growth 115.69%
- Ebitda 72.09%
- Net Worth 130.49%
- Total Assets 39.41%
About Acrannolife Genomics
Acrannolife Genomics Private Limited (AGPL) is a leading Private Limited Indian Non-Government Company incorporated in India on 31 July 2014 and has a history of Ten years and six months. Its registered office is in Chennai, Tamil Nadu, India.
The Company is engaged in the Life Sciences Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2023. It's a company limited by shares with an authorized capital of Rs 8.00 M and a paid-up capital of Rs 6.53 M.
The company currently has active open charges totaling ₹5.33 Cr.
Ramani Avinash and Agragesh Ramani serve as directors at the Company.
Company Details
- Location
Chennai, Tamil Nadu, India
- Telephone
+91-XXXXXXXXXX
- Email Address
- Website
- Social Media
Corporate Identity Details
- CIN/LLPIN
U73100TN2014PTC096751
- Company No.
096751
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
31 Jul 2014
- Date of AGM
30 Sep 2023
- Date of Balance Sheet
31 Mar 2023
- Listing Status
Unlisted
- ROC Code
Roc Chennai
Industry
Who are the key members and board of directors at Acrannolife Genomics?
Board Members (2)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Ramani Avinash  | Director | 31-Jul-2014 | Current |
| Agragesh Ramani | Director | 31-Jul-2014 | Current |
Financial Performance of Acrannolife Genomics.
Acrannolife Genomics Private Limited, for the financial year ended 2023, experienced significant growth in revenue, with a 52.78% increase. The company also saw a substantial improvement in profitability, with a 115.69% increase in profit. The company's net worth Soared by an impressive increase of 130.49%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metrics |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Acrannolife Genomics?
In 2023, Acrannolife Genomics had a promoter holding of 58.43% and a public holding of 41.57%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Charges (Loans)
₹53.30 M
₹0
Charges Breakdown by Lending Institutions
- Others : 4.00 Cr
- State Bank Of India : 1.33 Cr
Latest Charge Details
| Date | Lender | Amount | Status |
|---|---|---|---|
| 28 Feb 2024 | Others | ₹2.00 Cr | Open |
| 28 Feb 2024 | Others | ₹2.00 Cr | Open |
| 28 Dec 2018 | State Bank Of India | ₹1.33 Cr | Open |
How Many Employees Work at Acrannolife Genomics?
Acrannolife Genomics has a workforce of 0 employees as of Apr 09, 2024. Unlock access to detailed historical data on individuals associated with the company, including employment records, contributions to the Employees' Provident Fund Organization (EPFO), and other related insights.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Acrannolife Genomics, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Acrannolife Genomics's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.